Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications

Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications

Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but...

Full description

Bibliographic Details
Main Authors: Luca Tonella, Valentina Pala, Renata Ponti, Marco Rubatto, Giuseppe Gallo, Luca Mastorino, Gianluca Avallone, Martina Merli, Andrea Agostini, Paolo Fava, Luca Bertero, Rebecca Senetta, Simona Osella-Abate, Simone Ribero, Maria Teresa Fierro, Pietro Quaglino
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
melanoma
stage III
biomarkers
adjuvant therapy
Online Access:https://www.mdpi.com/1422-0067/22/9/4561

Internet

https://www.mdpi.com/1422-0067/22/9/4561

Similar Items